Positive airway pressure adherence and subthreshold adherence in posttraumatic stress disorder patients with comorbid sleep apnea

This article was published in the following Dove Press journal: Patient Preference and Adherence

Study objectives: Patients with comorbid posttraumatic stress disorder (PTSD) and obstructive sleep apnea (OSA) manifest low adherence to continuous positive airway pressure (CPAP) due to fixed, pressure-induced expiratory pressure intolerance (EPI), a subjective symptom and objective sign aggravated by anxiety sensitivity and somatosensory amplification. As advanced PAP therapy modes (ie, auto-bilevel PAP [ABPAP] or adaptive servo-ventilation [ASV]) may address these side effects, we hypothesized such treatment would be associated with decreased expiratory intolerance and increased adherence in posttraumatic stress patients with co-occurring OSA.

Methods: We reviewed charts of 147 consecutive adult patients with moderately severe posttraumatic stress symptoms and objectively diagnosed OSA. All patients failed or rejected CPAP and were manually titrated on auto-adjusting, dual-pressure ABPAP or ASV modes in the sleep laboratory, a technique to eliminate flow limitation breathing events while resolving EPI. Patients were then prescribed either mode of therapy. Follow-up encounters assessed patient use, and objective data downloads (ODDs) measured adherence.

Results: Of 147 charts reviewed, 130 patients were deemed current PAP users, and 102 provided ODDs: 64 used ASV and 38 used ABPAP. ODDs yielded three groups: 59 adherent per insurance conventions, 19 subthreshold compliant partial users, and 24 noncompliant. Compliance based on available downloads was 58%, notably higher than recently reported rates in PTSD patients with OSA. Among the 19 partial users, 17 patients were minutes of PAP use or small percentages of nights removed from meeting insurance compliance criteria for PAP devices.

Conclusion: Research is warranted on advanced PAP modes in managing CPAP failure in PTSD patients with comorbid OSA. Subthreshold adherence constructs may inform clinical care in a patient-centric model distinct from insurance conventions. Speculatively, clinical application of this transitional zone ("subthreshold" number of hours) may increase PAP use and eventual adherence.

Keywords: obstructive sleep apnea, upper airway resistance syndrome, CPAP, compliance, auto-bilevel, adaptive servo-ventilation

Plain language summary

Obstructive sleep apnea (OSA), a sleep breathing disorder, frequently co-occurs among patients with posttraumatic stress disorder (PTSD), a mental health condition arising after traumatic experiences. Continuous positive airway pressure (CPAP) therapy is the standard OSA treatment that pushes air through the nose or mouth, functioning as a physiological stent to maintain airway patency. CPAP failure is common in PTSD patients, possibly due to expiratory pressure intolerance triggered by fixed pressurized air delivery in which the patient reports difficulty breathing against the incoming air flow. Advanced positive airway pressure (PAP) devices known as...
auto-bilevel PAP and adaptive servo-ventilation can be manually tested in the sleep laboratory to decrease expiratory intolerance in order to improve patient comfort and thereby increase use. These objectives are achieved with advanced PAP by diminishing the volume of pressurized air against which the patient breathes during exhalation. Some research suggests PTSD patients using advanced devices will use their PAP machines more consistently. In our study, advanced PAP was associated with PAP adherence rates higher than typically observed in PTSD patients using CPAP.

Introduction

The prevalence of comorbid PTSD and OSA appears to be much higher than previously recognized. The gold standard intervention for OSA is CPAP therapy, and therapeutic effects are most apparent among patients achieving adherence to therapy. Interestingly, both older research and very recent studies also indicate treatment of OSA in PTSD patients is associated with decreased PTSD symptom severity. Unfortunately, trauma survivors demonstrate low adherence rates or partial use for PAP therapy. Lettieri et al reported PTSD/OSA patients used PAP on 53.3±35.6% of nights for an average of 3.4±2.8 hours/night, but only 30.2% were adherent per standard insurance compliance metrics compared to 55.1% of OSA patients without PTSD. In a recent study examining the effects of PAP therapy on PTSD symptoms, Orr et al assessed 59 patients prescribed a device, yet only 12 (20%) were compliant at 6-month follow-up. Another 15 patients were using prior to being lost to follow-up, and half were probably adherent, yielding an approximate overall compliance rate of 34%. In contrast to these low adherence rates, Orr et al demonstrated very high partial use rates in their sample; for example, at 3 months, although 18 patients were lost to follow-up, the remaining 41 patients were all using their devices at least some of the time. At 6 months, after another 9 patients were lost to follow-up, 81% of the remaining 32 patients were still using PAP.

Low adherence and partial use of PAP are widespread among sleep apnea patients in the general population, and more so in psychiatric patients with OSA comorbidity. Poor PAP compliance is typically investigated through frameworks attending to behavioral change models, psychoeducation, and other coaching strategies; and, many clinical practice models have been researched and described to improve adherence though few address the issue of partial use, an outcome incisively explored by Stepnowsky et al. Though partial use (subthreshold adherence) research studies are sparse, they have consistently demonstrated improved clinical outcomes, most notably daytime sleepiness. Such exploratory findings in subthreshold adherence suggest a potential value in defining the clinical importance of partial PAP use. However, research on partial use in PTSD patients is even more scarce, perhaps due to the influences of insurance carriers on dispensing PAP devices wherein subjective outcomes are often relegated to objective duration of use.

Our clinic implements a compliance protocol also focusing on psychological attributes, but we differ from conventional approaches by targeting the patient’s experiential and emotional reactions to pressurized air. In brief, psychiatric patients exposed to CPAP are susceptible to the problems of anxiety sensitivity and somatosensory amplification. In our clinical experience, both of these transdiagnostic vulnerabilities are triggered when attempting to use fixed pressurized air. As CPAP delivers the same pressure setting on inspiration and expiration for any given breath, the patient is always exhaling against a pressure greater than required to maintain a patent airway, an objectively proven observation described in the sleep literature since 1990. This fixed pressure on exhalation often produces an uncomfortable sensation sufficient to trigger PAP intolerance, and in vulnerable patients, claustrophobic or panic reactions flare up. Thus, at our sleep medical center, which specializes in the treatment of psychiatric patients with sleep disorders, we observe CPAP technology itself as a major cause of low adherence or outright rejection.

We recently reported on this phenomenon in a consecutive series of psychiatric patients with comorbid OSA or UARS. Using CMS criteria, we measured adherence (>4 hours/night on >70% of nights) and subthreshold compliance (subcompliant regular users, who were PAP users not meeting CMS guidelines but who averaged regular, nightly use >3 hours/night) in 113 patients naïve to treatment who failed CPAP and subsequently filled prescriptions for advanced PAP devices. Among 113 patients, 104 (92%) were current users at 7-month follow-up. ODDs available for 93 patients showed 59 adherent, averaging 42.0 (SD 12.1) hours/week, and 21 subthreshold compliant (partial users), averaging 18.0 (SD 5.6) hours/week. Adherence equaled 63% for patients with ODDs; another 10 partial users achieved levels minutes removed from the 4 hours/night criteria or a few percentage points from attaining 70% of nights criteria for adherence.

The advanced PAP modes applied in the prior and current research were dual-pressure, auto-adjusting devices, manually titrated in the sleep laboratory, that is, ABPAP or ASV, the latter in those qualifying for complex sleep apnea, a condition in which iatrogenic central apneas...
emerge upon exposure to CPAP. As described elsewhere, advanced PAP technology has been associated with reversing CPAP failure, improving adherence in chronic insomnia patients with comorbid OSA/UARS, decreasing residual sleepiness, and yielding higher-than-usual rates of compliance in psychiatric patients.

The use of manually titrated, advanced PAP technology derives from our sleep center’s 2005 policies and procedures, emphasizing the need to address the adverse experiences reported by patients while attempting CPAP technology.

To reiterate, the model was formulated to address “claustrophobic tendencies” in psychiatric or other patients who demonstrate anxiety sensitivity or somatosensory amplification to pressurized air, often appearing as awkward attempts to overcontrol one’s breathing while struggling to adapt to PAP. This pressure-related distress manifests as subjective (awake) or objective (asleep) EPI, and usually both problems emerge during titration PSG. As the patient struggles to gain sufficient air or fights smothering sensations from excessive air, claustrophobic tendencies emerge, which for vulnerable patients leads to rapid termination of the titration procedure, culminating in the patient displacing the mask. Among patients who continue to use the device, central apneas and eventually complex sleep apnea may emerge.

While some research focuses on the mask as the restrictive element triggering claustrophobic tendencies, in our experience, most patients with mask difficulties report discomfort or poor fit and request a different mask, whereas only a small proportion report restrictive sensations triggering claustrophobic tendencies. For example, in a recent study on adherence, >50% of patients with claustrophobia requested a full-face mask when filling their PAP prescriptions, a counterintuitive finding. In contrast, the distress related to pressurized air is the more common instigating complaint as patients frequently exclaim, “I just cannot breathe with the device” or “the machine is trying to control my breathing”. As one patient recently remarked, “It feels like driving a motorcycle without a wind visor”. Paradoxically, mask issues may signal a covert pressure intolerance problem.

For PTSD patients already suffering high levels of anxiety and anxiety sensitivity, both generalized pressure intolerance and EPI-induced claustrophobic tendencies may arise during the process of somatosensory amplification. Anecdotally, vulnerable PTSD patients’ attempts at PAP may deteriorate to an unambiguous phobic response, after which they avoid further trials. Likewise, some patients describe these events as traumatizing, and this conceptualization is supported by subsequent treatment avoidance behavior or long lapses between the initial traumatizing PAP experience and efforts to reattempt PAP therapy.

The current retrospective chart review examined a consecutive series of OSA/UARS patients with moderately severe posttraumatic stress symptoms, presumptively diagnosed with chronic PTSD and prescribed PAP therapy. We hypothesized the use of advanced PAP technology would be associated with two outcomes: 1) 50% adherence in a sample of patients previously experiencing CPAP failure, intolerance, or rejection; and 2) a substantial subgroup would achieve subthreshold adherence (partial use), leaving them just shy of CMS-derived compliance.

**Methods**

**Informed consent**

Patients provided consent during completion of the online intake at MSAS to use their information anonymously for research purposes. All data were de-identified for this case series. The intake questionnaire assessed sleep symptoms based on nosology for sleep disorders in the International Classification of Sleep Disorders. The Los Alamos Medical Center Institutional Review Board found the chart review exempt because it was a retrospective analysis of a de-identified dataset, and patients received no experimental procedures or interventions.

**Sample and inclusion criteria**

This retrospective chart review included adult patients (≥18 years old), presenting to MSAS between December 2009 and January 2016, who 1) reported a history of traumatic exposure and scored ≥21 on the PSS; 2) were diagnosed with OSA (AHI ≥5) or UARS (AHI <5 and RDI ≥15) during objective sleep testing; 3) failed CPAP therapy during titration or at home; 4) completed an attended, manual titration (or split-therapy PSG) of an advanced auto-titrating device (ABPAP or ASV); and 5) filled a prescription for ABPAP or ASV therapy with attempted home use (Figure 1). After starting the chart review with 229 eligible patients with PSS ≥21 and a diagnosis of sleep-disordered breathing, 47 did not complete titration PSG. Of the remaining 182, 35 did not fill their prescription for PAP, leaving 147 patients who attempted PAP. Of the 147 PAP attempters, 130 were current PAP users (Figure 1 provides the use criteria) at follow-up, and 17 were nonusers (8 returned device to DME; 9 lost to follow-up). ODDs were available for 102 of the 130 current users. A significantly larger proportion of users with ODD (76.5%) were anxiety cluster positive compared to users without ODD (53.6%; P=0.02).
was no difference in the remaining psychiatric histories between the two groups. Comparison of sociodemographics, PTSD symptoms scores, subjective intake sleep indices, and objective sleep breathing indices between our final sample of 102 users with ODD and the 28 current users without ODD yielded no significant differences.

**PAP titration protocol**

An overarching premise embedded within our policies and procedures is the well-documented fact that early experiences with PAP are highly predictive of success or failure.\(^{20,61-64}\) When we encounter patients with high probability for CPAP failure, we err on the side of a proactive practice model focusing on the individual’s early subjective experiences with the CPAP mode. Although for insurance purposes any patient must “fail” CPAP to be switched to an advanced form of PAP, there are no formal criteria for CPAP failure. In these circumstances where an individual develops an immediate panicky or frank claustrophobic response when attempting to breathe outward against continuous pressure delivered inward, further attempts at patient persuasion by the physician or sleep technologist to “try a little harder” with CPAP may prove counterproductive. More commonly, pushing this incipient failing strategy often elicits emotional responses from the patient, including frustration, discouragement, anxiety, and fear.\(^{43}\)

In these early attempts at PAP initiation, acceptance, and adaptation, discretion has guided us to switch the individual to an expiratory relief mode, which may rapidly enhance the patient’s level of comfort and evoke a more positive attitude. During the course of the titration itself as these patients manifest objective expiratory tolerance, even with APAP, EPR, or BPAP devices, we attempt to smooth out the airflow signal\(^{65}\) with the use of ABPAP or ASV devices, the
latter when meeting complex sleep apnea diagnosis (CAI ≥5, CAI/AHI >50%).

Central apneas are not uncommon at higher elevations (Albuquerque, NM [elev. 1,627.6 meters]) or among anxiety patients prone to hyperventilation that may trigger CO₂ decrements and resultant drop off in breathing drive (loop gain).

When manually titrated, the sleep technologist overrides the aspects of the auto-adjusting algorithms that appear to have responded ineffectually to the dueling problems of residual flow limitation and iatrogenic EPI. As described elsewhere, this nuanced approach to titrations often requires changes in the 0.2- to 0.4-cm H₂O range, while adjusting both inspiratory and expiratory settings. Although our experience reflects case series, we have published on this clinical care model, involving 744 OSA/UARS patients, and have treated 3,934 clinical patients in this manner at our sleep center from 2008 to the present.

As an aside, as long as patients attempt standard PAP modes during the presleep desensitization or the titration PSG or through home use, subsequent subjective or objective failure of the treatment usually provides sufficient grounds for insurance purposes to escalate the patient’s care to receive a trial with an advanced PAP mode. In our extensive clinical experience, the manual titration of ABPAP or ASV in the sleep laboratory has proven consistently superior to home use of prescribed, default settings for these advanced devices. Thus, the sleep laboratory plays a critical role in this protocol.

Adherence metrics
The 102 patients with objective compliance data were divided into three subgroups: C-RU, patients averaging ≥4 hours/night on ≥70% of nights used, thus meeting CMS criteria; SC-RU, patients using PAP regularly with average nightly use ranging from 3 to almost 6 hours per night but not meeting the 4 hours of use on 70% of nights for compliance; and NC-MU, patients with minimal PAP use and averaging <2 hours/night. Rare differences were noted in baseline characteristics among the three groups (Table 1). We also calculated compliance using an alternate metric based on total weekly PAP hours derived from Medicare criteria where their minimum of 4 hours/night on 4.9 nights/week totaled 19.6 hours/week. Rounding up to 20 hours/week, we defined two groups: adherent, averaging >20 hours/week and non-adherent, averaging <20 hours/week.

Data analysis
One-way ANOVA compared continuous variables, and Hedge’s g calculated effects between unequal-sized subsamples. Chi-square analyzed dichotomous variables, and effect sizes were based on proportional differences between groups. A P-value of 0.05 was considered statistically significant. Data were analyzed with IBM SPSS Statistics, version 11.0 for Windows, 2002 (IBM Corporation). All continuous variables are expressed as mean (SD).

Results
Sociodemographics and baseline sleep metrics
The final 102 patients were predominantly middle aged (average age = 49.0 years), overweight (average BMI = 32.5), Caucasian (55.9%) or Hispanic (32.4%), females (56.0%) who were married/living with partner (55.9%), and completed some college or less (62.8%). At intake, the mean PSS score (30.63 [8.03]) equated to moderately severe symptoms, mean ISI score (20.53 [4.66]) moderately severe insomnia, and mean Epworth Sleepiness Scale score (11.34 [6.48]) was in the mild range for daytime sleepiness (Table 1). The average time to follow-up was 12.72 (12.71) months.

Nearly 90% of patients were diagnosed with OSA (n=88), and the remainder suffered UARS (n=12) and primary central sleep apnea (n=2). By diagnostic breathing event indices, sleep breathing was severe based on RDI, moderate based on AHI, and very mild based on CAI. Ultimately, 64 patients (62.75%) were diagnosed with complex sleep apnea, necessitating the use of ASV mode of treatment (Table 1). Thirty-eight remaining patients used ABPAP.

CMS compliance metric
By standard CMS compliance metrics (Figure 1), there were 59 C-RU, 19 SC-RU, and 24 NC-MU patients. Thus, 58% of patients were compliant, and 42% noncompliant. On ODD among the 43 noncompliant patients, there were 19 SC-RU patients (partial users) within minutes from averaging 4 hours/night or a few percentage points from attaining adherence on 70% of nights. And, 17 of 19 SC-RU patients averaged >4 hours of PAP use on nights used yet were noncompliant due to insufficient nights used per week. PTSD symptom severity and insomnia severity did not correlate significantly with adherence status, albeit small nonsignificant effects were present demonstrating higher PSS and ISI scores in the non-adherent group compared to the adherent group (Table 1).

Figure 2 highlights SC-RU patients’ PAP use relative to C-RU and NC-MU patients. The boxed area demarcates a “transitional zone” comprising 3–6 hours of nightly use (horizontal sides of box) and 10–30 hours of weekly use (vertical sides of box). Note the two C-RU patients
Table 1 Comparison of intake PSS, ISI, and ESS total scores, subjective sleep indices, psychiatric history, objective sleep breathing diagnostic data, and objective titration data for complex sleep apnea cases

<table>
<thead>
<tr>
<th>Measures</th>
<th>Total sample (n=102)</th>
<th>C-RU (n=59)</th>
<th>SC-RU (n=19)</th>
<th>NC-MU (n=24)</th>
<th>P or C value</th>
<th>C-RU vs NC-MU Effect size</th>
<th>SC-RU vs NC-MU Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intake questionnaire scores</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSS, total score</td>
<td>30.63 (8.03)</td>
<td>29.71 (7.46)</td>
<td>31.16 (7.38)</td>
<td>32.46 (9.73)</td>
<td>P=0.35</td>
<td>0.33</td>
<td>0.15</td>
</tr>
<tr>
<td>ISI, total score</td>
<td>20.53 (4.66)</td>
<td>20.10 (4.95)</td>
<td>20.21 (4.88)</td>
<td>21.83 (3.55)</td>
<td>P=0.30</td>
<td>0.37</td>
<td>0.38</td>
</tr>
<tr>
<td>ESS, total score</td>
<td>11.34 (6.48)</td>
<td>11.41 (6.50)</td>
<td>11.74 (6.76)</td>
<td>10.88 (6.44)</td>
<td>P=0.91</td>
<td>0.08</td>
<td>0.13</td>
</tr>
<tr>
<td>Subjective sleep indices</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOL (minutes)</td>
<td>95.82 (99.06)</td>
<td>90.39 (95.61)</td>
<td>93.47 (84.01)</td>
<td>111.04 (119.15)</td>
<td>P=0.69</td>
<td>0.20</td>
<td>0.16</td>
</tr>
<tr>
<td>TIB (hours)</td>
<td>8.03 (1.86)</td>
<td>8.10 (1.66)</td>
<td>7.69 (1.81)</td>
<td>8.15 (2.36)</td>
<td>P=0.68</td>
<td>0.03</td>
<td>0.21</td>
</tr>
<tr>
<td>TST (hours)</td>
<td>5.65 (1.73)</td>
<td>5.93 (1.47)</td>
<td>5.74 (1.81)</td>
<td>4.88 (2.06)</td>
<td>P=0.04</td>
<td>0.63</td>
<td>0.43</td>
</tr>
<tr>
<td>SE (%)</td>
<td>71.86 (19.09)</td>
<td>74.55 (16.71)</td>
<td>76.93 (20.88)</td>
<td>61.21 (19.93)</td>
<td>P=0.01</td>
<td>0.75</td>
<td>0.76</td>
</tr>
<tr>
<td>WASO (minutes)</td>
<td>135.67 (119.31)</td>
<td>117.14 (108.30)</td>
<td>104.89 (106.37)</td>
<td>205.58 (131.58)</td>
<td>P=0.003</td>
<td>0.76</td>
<td>0.82</td>
</tr>
<tr>
<td>Psychiatric history</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychiatric history positive</td>
<td>100 (98.04)</td>
<td>57 (96.61)</td>
<td>19 (100.00)</td>
<td>24 (100.00)</td>
<td>C=0.12</td>
<td>3.39%</td>
<td>0.00%</td>
</tr>
<tr>
<td>Anxiety cluster positive</td>
<td>78 (74.67)</td>
<td>44 (74.58)</td>
<td>14 (73.68)</td>
<td>20 (83.33)</td>
<td>C=0.09</td>
<td>8.75%</td>
<td>9.65%</td>
</tr>
<tr>
<td>Depression cluster positive</td>
<td>84 (82.35)</td>
<td>46 (77.97)</td>
<td>18 (94.74)</td>
<td>20 (83.33)</td>
<td>C=0.16</td>
<td>5.36%</td>
<td>−11.41%</td>
</tr>
<tr>
<td>Objective diagnoses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OSA</td>
<td>88 (86.27)</td>
<td>51 (86.44)</td>
<td>16 (84.21)</td>
<td>21 (87.50)</td>
<td>C=0.13</td>
<td>1.06%</td>
<td>3.29%</td>
</tr>
<tr>
<td>UARS</td>
<td>12 (11.76)</td>
<td>6 (10.17)</td>
<td>3 (15.79)</td>
<td>3 (12.50)</td>
<td>−0.35%</td>
<td>−3.29%</td>
<td></td>
</tr>
<tr>
<td>Primary CSA</td>
<td>2 (1.96)</td>
<td>2 (3.39)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>−2.39%</td>
<td>−</td>
<td></td>
</tr>
<tr>
<td>Objective breathing indices</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RDI events/hour</td>
<td>56.52 (31.98)</td>
<td>55.45 (35.69)</td>
<td>60.20 (29.14)</td>
<td>55.81 (26.17)</td>
<td>P=0.86</td>
<td>0.01</td>
<td>0.16</td>
</tr>
<tr>
<td>AHF events/hour</td>
<td>26.14 (28.01)</td>
<td>28.66 (32.14)</td>
<td>21.42 (24.48)</td>
<td>23.76 (18.49)</td>
<td>P=0.56</td>
<td>0.17</td>
<td>0.11</td>
</tr>
<tr>
<td>CAI events/hour</td>
<td>2.75 (8.35)</td>
<td>3.93 (10.50)</td>
<td>0.89 (1.63)</td>
<td>1.75 (5.86)</td>
<td>P=0.34</td>
<td>0.23</td>
<td>0.19</td>
</tr>
<tr>
<td>RERAI events/hour</td>
<td>31.35 (24.82)</td>
<td>28.30 (23.37)</td>
<td>38.78 (27.35)</td>
<td>31.71 (25.45)</td>
<td>P=0.30</td>
<td>0.14</td>
<td>0.26</td>
</tr>
<tr>
<td>CompSA diagnosis/index</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complex sleep apnea</td>
<td>64 (62.75)</td>
<td>33 (55.93)</td>
<td>15 (78.95)</td>
<td>16 (66.67)</td>
<td>C=0.18</td>
<td>10.74%</td>
<td>−12.28%</td>
</tr>
<tr>
<td>CAI (events/hour)</td>
<td>15.59 (23.21)</td>
<td>14.79 (23.38)</td>
<td>15.76 (14.73)</td>
<td>17.53 (28.44)</td>
<td>P=0.90</td>
<td>0.11</td>
<td>0.07</td>
</tr>
<tr>
<td>AHF (events/hour)</td>
<td>18.90 (27.02)</td>
<td>18.19 (28.06)</td>
<td>19.22 (16.90)</td>
<td>20.51 (31.31)</td>
<td>P=0.94</td>
<td>0.08</td>
<td>0.05</td>
</tr>
<tr>
<td>CAI/CAI ratio</td>
<td>81.03 (16.48)</td>
<td>81.61 (16.42)</td>
<td>83.49 (14.45)</td>
<td>77.71 (18.55)</td>
<td>P=0.67</td>
<td>0.23</td>
<td>0.34</td>
</tr>
</tbody>
</table>

Notes: Continuous variables are expressed as mean (SD), whereas dichotomous variables are expressed as total count (%) of columns. *P-values were determined using ANOVA for continuous variables. Contingency coefficient (C) was used for comparison of dichotomous variables. Effect sizes were determined using unequal sample sizes expressed as Hedge’s g for continuous variables and as percentage differences for dichotomous variables; NC-MU was used as reference group for comparisons. **PSS scores ≥21 are consistent with moderate-to-severe PTsD symptom severity. *ISI scores ≥15 are indicative of clinically significant insomnia. **ESS scores >10 are indicative of clinically significant daytime sleepiness. 1 Anxiety cluster – subjective report of at least one of the following psychiatric conditions: anxiety disorder, panic attacks, or obsessive–compulsive disorder. **Depression cluster – subjective report of at least one of the following psychiatric conditions: depression or manic depression. **RDI – total apneas + total hypopneas + total RERAI/hours of sleep. **AHF – total apneas + total hypopneas/hours of sleep. **CAI >5 and AHF/CAI >50.**

Abbreviations: PSS, PTSD Symptom Scale; ISI, Insomnia Severity Index; ESS, Epworth Sleepiness Scale; C-RU, compliant regular users; SC-RU, sub-compliant regular users; NC-MU, noncompliant minimal users; SOL, sleep onset latency; TIB, time in bed; TST, total sleep time; SE, sleep efficiency; WASO, wake after sleep onset; OSA, obstructive sleep apnea; UARS, upper airway resistance syndrome; CS-A, central sleep apnea; RDI, respiratory disturbance index; AHF, apnea–hypopnea index; CAI, central apnea index; RERAI, RERA index; CompSA, complex sleep apnea; PTSD, posttraumatic stress disorder; RERAs, respiratory effort-related arousals.

(last black squares) within this transitional zone were deemed CMS compliant, whereas by comparison numerous SC-RU patients (gray diamonds) exceeded the nightly or the weekly hours of use of these two compliant patients, including 17 who documented ≥20 weekly hours. As seen in Figure 2, 15 of 19 SC-RU patients averaged >4 hours/night but were noncompliant due to not meeting the CMS 70% requirement. One example (circled gray diamond) is the patient who averaged 4.0 hours/night and 28.0 hours/week but was noncompliant because PAP use was 7 hours on 4 of 7 nights of the week, thus achieving compliance on only 56% of nights. Last, of potential clinical import, the proportions of ASV and ABPAP users were nearly identical for C-RU and NC-MU groups, but the SC-RU group demonstrated a significantly higher proportion of patients using ASV (n=15) compared to ABPAP (n=4) (contingency coefficient =0.50). Regarding residual breathing events on ODD, there was no significant difference (P=0.50) in AHF between C-RU (2.10 [3.11] events/hour) and SC-RU (2.68 [4.04]) patients.

Alternate metric (weekly use hours)

Rounding up to 20 hours/week, our sample would have yielded an additional 17 patients for an adherence total of
74.5% (76/102 patients) and a non-adherence total of 25.5% (26/102 patients) if CMS permitted total hours of use for adherence criteria.

**Discussion**

This research provides evidence for the use of advanced PAP therapies such as ABPAP or ASV to treat subjective and objective EPI in PTSD patients who failed CPAP therapy for the treatment of their comorbid OSA or UARS. The findings are consistent with a clinically meaningful comfort effect that counters distress experienced by patients with anxiety sensitivity or somatosensory amplification who struggle to exhale against fixed pressurized airflow. Due to the retrospective, uncontrolled design of the study, however, these findings can only be classified as an association.

This study also highlights the lack of a patient-centric perspective in the CMS compliance metric, which could have led to termination of therapy in 17 patients (Figure 2, gray diamonds) who were minutes or portions of nights removed from the 4 hours/70% nights standard despite >20 hours/week of use. Given the time course required for vulnerable psychiatric patients to adapt to PAP therapy, we have previously raised the question on whether the concept of hours of use is a more pragmatic and appropriate metric in the management of more complex sleep-disordered breathing patients, which also aligns with Stepnowsky's “dose–response” model of PAP care. Moreover, by neglecting this clinical care principle, current insurance directives may discourage subthreshold partial PAP users who need a longer interval of adaptation to meet coverage standards; likewise, a partial use framework would also promote a longer transitional window for problem-solving mask and pressure complaints as well as other adaptation issues, all essential ingredients to achieving adherence.

Along the same lines, whereas adherence is largely an insurance-driven policy, partial use offers the potential for a patient-centric model of care because the latter provides opportunities to more accurately investigate dose–response relationships between the symptoms reported by sleep-disordered breathing patients and hours of use, a more precise continuous variable. In our recent study on adherence, outcomes improved in subthreshold compliant patients, and small correlation coefficients indicated that increasing hours of use were associated with decreasing symptoms of insomnia ($r=0.20$) and nocturia episodes ($r=0.25$). On the other hand, Orr et al.'s study demonstrated a small effect for decreased PTSD symptoms associated with an increased number of nights used, whereas neither hours of use nor number of nights >4 hours showed significant effects for improvement in PTSD symptoms, albeit their sample size was small. Once again, these distinctions highlight how the two constructs of adherence and use may lead to paradoxical findings, which may interfere with our ability to more effectively treat OSA and UARS patients. Prospective research is needed to determine the clinical advantages and disadvantages in the application of adherence or use.

The current study is limited by the retrospective, uncontrolled design. Future studies using randomized controlled trials may investigate the benefits of advanced vs traditional PAP devices in PTSD patients with comorbid sleep-disordered breathing. And prospective studies should also compare outcomes between PTSD and non-PTSD patients with OSA to discern how clinical care models may require different resources for each group. In particular, studies should compare the adherence rates of physician-prescribed APAP pressure ranges at setup (per Orr et al.) vs in-laboratory, manually titrated settings for dual-pressure auto-adjusting devices. In addition, selection bias is a concern in this cohort because we were unable to obtain data downloads in 28 (22%) of the user group and thus could not confirm if they were adherent, albeit it is worth reiterating that based on our clinical follow-up encounters, 130 (88%) of these 147 total PAP attempts appeared to be current users.
This distinction between use and adherence raises another clinical question on how to delineate the proper baseline in a sample of PAP patients assessed for adherence. We chose a construct similar to Orr et al (“willingness-to-use PAP”) by creating a baseline of patients who filled a PAP prescription. Arguments, pro and con could be made to use more or less stringent starting points in determining adherence rates in various cohorts of OSA/UARS patients.

In summary, though not well described in the sleep literature, certain sleep-disordered breathing patients describe CPAP attempts as “traumatizing experiences”. Related theories point to the potential for a CPAP user to experience a phobic response to the mask itself or pressurized air, and OSA patients may also be susceptible to activation of a “false suffocation alarm” due to rapid changes in carbon dioxide, leading to panic attacks. Taken together, at-risk OSA patients with anxiety disorders, as the best examples, are already vulnerable to claustrophobic tendencies prior to attempting CPAP because they are at risk for anxiety sensitivity and somatosensory amplification. When initiating fixed pressurized air treatment, these patients develop intolerance and irregular breathing patterns, including instances of iatrogenic central apneas. PTSD patients in particular and psychiatric patients in general who cannot adapt rapidly to PAP therapy may be served by monitoring their graded levels of adherence through which they would be encouraged to traverse steps from minimal use to subthreshold levels (partial users) and eventually full adherence during extended time periods. These time frames may prove longer than the standard 60- to 90-day CMS mandated window for clinical follow-up. A testable hypothesis is proposed to determine whether advanced PAP modes facilitate this process.

**Abbreviations**

ABPAP, auto-bilevel PAP; AHI, apnea–hypopnea index; APAP, auto-CPAP; ASV, adaptive servo-ventilation; BPAP, bilevel positive airway pressure; CAI, central apnea index; CMS, Center of Medicare and Medicaid Services; CPAP, continuous positive airway pressure; C-RU, compliant regular PAP users; EPI, expiratory pressure intolerance; EPR, expiratory pressure relief; ISL, insomnia severity index; MSAS, Maimonides Sleep Arts & Sciences; NC-MU, non-compliant minimal PAP users; ODD, objective data download; OSA, obstructive sleep apnea; PAP, positive airway pressure; PSG, polysomnography; PSS, PTSD Symptom Scale; PTSD, posttraumatic stress disorder; RDI, respiratory disturbance index; SC-RU, sub-compliant regular PAP users; UARS, upper airway resistance syndrome.

**Acknowledgments**

The authors thank the Los Alamos Medical Center and the Los Alamos Medical Center Sleep Laboratory for administrative and clinical assistance in the completion of this research project.

**Author contributions**

Ms Obando and Mr Ulibarri were responsible for acquisition of data. Ms Obando, Mr Ulibarri, Dr Krakow, and Ms McIver were responsible for data analysis and interpretation. Dr Krakow was responsible for the conception and design of the study. All authors contributed to the revision of manuscript, approved the final manuscript version for publication, and have agreed to be accountable for all aspects of this manuscript.

**Disclosure**

Dr Krakow is involved in six main activities related to his work on sleep medicine: He owns and operates six sites that provide education and offer products and services (www.nightmarestreatment.com, www.ptsdsleepclinic.com, www.sleeptreatment.com, www.sleepdynamictherapy.com, www.soundsleepsoundmind.com, and www.nocturiacures.com). He is the medical director of a national DME company Classic Sleep Care in which his sole functions are consultation and QA; he has neither patient encounters nor does he benefit from the sale of any DME equipment. He markets and sells three books for patients with sleep disorders (Insomnia Cures, Turning Nightmares into Dreams, and Sound Sleep, Sound Mind). He owns and operates one commercial sleep center (Maimonides Sleep Arts & Sciences). He conducts CME/CEU educational programs for medical and mental health providers to learn about sleep disorders. Sometimes, programs involve the attendee paying a fee directly to their center. Other times, the workshops at other locations may be paid for by vendors such as Respironics and RESMED or other institutions such as the AMEDDC&S, VAMC, and regional sleep center conferences. He is the president of a nonprofit sleep research center, the Sleep & Human Health Institute (www.shhi.org), that occasionally provides consultation services or receives grants for pilot studies, the most recent of which was ResMed (~$400,000, January 2015, funding for randomized control trial of PAP treatment in insomnia patients). Ms Obando, Mr Ulibarri, and Ms McIver report no conflicts of interest in this work.

**References**